OpenAI's Policy, Research, and Science team has released a report advocating for the expanded use of AI in life sciences, highlighting the potential for AI to accelerate drug discovery and streamline research processes. The report, shared with Axios, calls for increased access to medical data, treating advanced AI as a national research resource, and boosting investment in infrastructure like computing power and laboratories. Despite these ambitions, no AI-discovered drug has yet passed Phase III trials, and the failure rate in Phase II remains similar to traditional methods. The report's recommendations include government support for open medical data access and prioritizing AI research resources, aiming to enhance market access for AI products. While AI promises to reduce drug development timelines, current clinical evidence does not fully support these claims. Meanwhile, Amazon has launched its AI-driven drug molecule generation tool, Bio Discovery, as tech giants vie for a foothold in this emerging sector.